AMENDMENT NO. 3 TO THE AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENTDare Bioscience, Inc. • March 30th, 2023 • Pharmaceutical preparations
This Amendment No. 3 to the Amended and Restated Exclusive License Agreement is entered into by and among Fred Mermelstein, Ph.D. and Janet Chollet, M.D. (the “Licensors”), Pear Tree Pharmaceuticals, Inc., a corporation duly organized and existing under the laws of the State of Delaware (the “Licensee”) and Bernadette Klamerus (“Klamerus”), effective as of February 13, 2017 (“Amendment No. 3 Effective Date”).
